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Pheochromocytomas are rare tumours with uncertain clinical behaviour. Histologi-
cal separation between benign and malignant pheochromocytomas is usually difficult.
The utilization of PASS criteria (Pheochromocytoma of the Adrenal Gland Scaled Score)
has not provided a solid basis for separating benign from malignant tumours. The aim
of this study was to investigate immunohistochemical markers (chromogranin, synap-
tophysin, S-100 and Ki-67) to find out if they could provide useful diagnostic and/or
prognostic data in a series of 62 pheochromocytomas (5 cases followed an aggressive
clinical course). Chromogranin and synaptophysin immunoreactivity proved to be di-
agnostically useful, allowing, together with the absence of immunoreactivity for in-
hibin and melan A, an unequivocal diagnosis of pheochromocytoma. The pattern of
staining did not provide, however, significant prognostic information. The mean count
of sustentacular S-100 positive cells was lower in malignant than in benign
pheochromocytomas but the frequent architectural variability and the haemorrhag-
ic and cystic changes make it very difficult to achieve a precise and reproducible count
in the majority of tumours. Without questioning that the occurrence of metastases
and/or recurrent disease still remains the only unquestionable criterion for diagnos-
ing a malignant pheochromocytoma, we think that the combined use of the PASS
score and Ki-67 index provides useful information for diagnosing malignancy.
Key words: benign pheochromocytoma, metastasising pheochromocytoma, diag-
nosis, immunohistochemistry.
Introduction
Pheochromocytomas are rare, catecholamine-pro-
ducing neuroendocrine tumours arising from chromaffin
cells of the adrenal medulla [1, 2]. Usually they are di-
agnosed in the fourth and fifth decade of life [3-5], but
they can occur at any age – the cases of early onset are
most commonly associated with hereditary syndromes:
multiple endocrine neoplasia type 2 syndrome
(MEN 2), neurofibromatosis (NF) or von Hippel-Lin-
dau syndrome (VHL) [6, 7]. The majority of pheochro-
mocytomas are detected because of symptoms associ-
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ated with hormone production and secretion: sustained
or paroxysmal hypertension, sweating, palpitations or
headaches [8]. About 25% of tumours are non-secreting
and are found incidentally during imaging studies of
the abdomen performed for unrelated reasons (so-called
incidentalomas) [8]. Malignant pheochromocytomas
are rare – they represent about 5 to 13% of all cases
[2, 6, 9-11]. The incidence of malignancy in tumours
that arise on the background of a germline SDHB mu-
tation is higher, up to 30% [7, 12]. The histological
separation between benign and malignant pheochro-
mocytomas is usually very difficult and the only un-
questionable criterion for diagnosis of malignancy still
remains the presence of metastases (defined by the find-
ing of tumour cells in sites where chromaffin cells are
normally absent to distinguish metastases from mul-
ti-focal disease) or, according to some authors, also re-
current disease [1, 6]. The most common metastatic
sites are lymph nodes, liver, lungs, and bones [2]. Pa-
tients with isolated bone metastases had better prog-
nosis than patients with liver and lung metastases [13].
The 5-year survival rate for patients with malignant
pheochromocytoma was 44-53% [14]. There is no sin-
gle histological or immunohistochemical criterion
which may predict the malignant behaviour of any sin-
gle tumour, thus justifying the efforts that are being
made to find a group of features which may allow one
to separate benign from malignant tumours. The best
known and most widely used multifactorial histolog-
ical system is PASS (Pheochromocytoma of the Adre-
nal Gland Scaled Score) proposed by Thompson in 2002
[15]. This system is rather complicated and includes
twelve histological features with different relative im-
pacts. There is growing evidence that PASS is not a per-
fect tool to distinguish benign from malignant
pheochromocytomas and that it has some limitations
[16]. The inter-observer and intra-observer agreements
have been reported to be unsatisfactory by some au-
thors [17-19].
The aim of this study was to determine whether the
use of several immunohistochemical markers could pro-
vide useful data for diagnosing and for predicting the
clinical outcome of patients with pheochromocytoma
in everyday pathomorphological practice.
Material and methods
A retrospective study of pheochromocytomas di-
agnosed in the Pathology Department of Jagiellonian
University in Cracow during a period of 15 years (from
1996 to 2010) was performed. The records of 274 pa-
tients with symptomatic and asymptomatic adrenal tu-
mours were reviewed in order to search for the diag-
nosis of pheochromocytoma. Sixty-seven tumours
with this diagnosis were found in the files of the Pathol-
ogy Department.
Haematoxylin and eosin-stained slides from 64 tu-
mours were looked up (in three cases the slides were
not available). All tumours were re-evaluated re-
garding their immunoreactivity for the following
antigens (Table I). Briefly, a representative section from
each tumour was selected for immunohistochemical in-
vestigation and 4 µm sections were prepared. The im-
munohistochemistry was performed by the standard
method: the slides were de-waxed, rehydrated and in-
cubated in 3% peroxide solution for 10 minutes to block
the endogenous peroxidase activity. Antigen retrieval
was carried out by microwaving in citrate buffer (for
chromogranin, melan A and Ki-67) and EDTA (for
synaptophysin and inhibin) for 5 minutes at 700 W,
then for 5 minutes at 600 W. The Lab-Vision detec-
tion system was used. The primary antibodies and the
respective technical details are summarised in Table I.
Chromogranin and synaptophysin staining was done
to confirm the neuroendocrine nature of the tumours
and S-100 to identify the presence of sustentacular cells.
Additional reactions with melan A and inhibin anti-
bodies were performed to evaluate the immunoreac-
tivity of pheochromocytoma cells with these two mark-
ers, which are known to be diffusely present in
lesions derived from the adrenal cortex. In each case,
the proliferation activity was estimated as the per-
centage of tumour cells positive for the proliferation
marker Ki-67.
Staining intensity with chromogranin and synap-
tophysin antibodies was graded as weak (1+), mod-
erate (2+) or strong (3+) and the percentage of pos-
itive cells was assessed. For Ki-67 antibody each slide
was examined under low power to identify the areas
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Table I. Primary antibodies used for immunohistochemical analysis
PRIMARY ANTIBODY PRE-TREATMENT MANUFACTURER DILUTION/ DETECTION
INCUBATION TIME METHOD
chromogranin citrate buffer Dako 1 : 600/30 min LabVision
synaptophysin EDTA Dako 1 : 100/30 min LabVision
S-100 – Dako 1 : 400/30 min LabVision
melan-A citrate buffer LabVision 1 : 20/30 min LabVision
inhibin EDTA Dako 1 : 25/60 min LabVision
Ki-67 citrate buffer Dako 1 : 100/60 min LabVision
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with the highest density of Ki-67 positive cells. The
proliferative index was expressed as a percentage of pos-
itively stained cells (counting at least 200 cells in
5 HPF). S-100 positive cells were counted in ten dif-
ferent, randomly selected high power fields (HPF).
Two out of the 64 selected cases were reclassified as
cortical tumours – one as adrenocortical carcinoma
(ACC) and another as adrenocortical adenoma (ACA)
– and were excluded from the study. Finally we had
analysed 62 pheochromocytomas diagnosed in 58 pa-
tients (four patients: three women and one man had
bilateral tumours).
Five of the 58 patients with pheochromocytoma
(8.6%) had malignant tumours (three pheochromo-
cytomas gave distant metastases and two recurred). All
pheochromocytomas with malignant clinical course were
unilateral. We obtained data on the follow-up of 48
of the other 57 cases (mean time of the follow-up: 45.6
months, median: 38 months). Nine cases were lost for
follow-up, but we know they were not treated for any
recurrence and/or metastasis in our department.
The Adrenal Gland Scaled Score (PASS) was eval-
uated according to the recommendations [15] in
every pheochromocytoma (n = 62) by one pathologist
(MB) who was not aware of the clinical history of the
cases.
Results
The HE slides and paraffin blocks of the 62 cases
of pheochromocytoma were available for reviewing and
recutting. Two of the cases represented composite
pheochromocytoma + ganglioneuroma. The group in-
cluded 28 females (three had bilateral tumours) and 30
males (one had bilateral tumours) ranging in age from
19 to 75 years (mean age 47.6 years, median: 48 years,
SD: 15.4). The mean age of male patients was high-
er than in the female group (48.4 years, range 19-75,
SD = 15.5 and 46.9 years, range 19-73, SD = 15.5
respectively). Thirty-four tumours (54.8%) were found
in the right adrenal whereas the left adrenal was in-
volved in 24 cases (in four cases the site of the tumour
was unknown) (Table 2). Seven patients were known
to have one of the syndromes associated with increased
incidence of adrenal pheochromocytoma (two patients
with MEN 2A syndrome, four with NF and one with
VHL syndrome). Three of these patients (two with
MEN 2A and one with NF syndrome) had bilateral tu-
mours. The mean tumour diameter was 4.98 cm (me-
dian: 4.2 cm, range 1.5-13 cm, SD = 2.38) with no
significant difference between male and female groups
(5.1 and 4.9 cm respectively). Five tumours dis-
played cysts filled with blood with only a thin rim of
neoplastic tissue at the periphery – the mean tumour
diameter in this group was higher (6.9 cm) than in the
entire pheochromocytoma group. Five out of 62
analysed tumours behaved in a malignant way (two of
them recurred and three gave rise to distant metastases)
– the mean tumour diameter in this group was
8.10 cm (median 7.0 cm, range: 5.5-13 cm, SD = 2.88)
(Table III).
The mean PASS score in the entire analysed group
was 4.36 with no difference between male and female
patients (4.35 and 4.37, respectively). In 28 cases (45%
of the tumours) the PASS score was lower than 4 and
in 34 cases (55% of the tumours) it reached or exceeded
the limit of 4 points. In the latter group, 16 tumours
scored 4 or 5 and in 18 tumours PASS reached 6 or
more points. In the group of five tumours which dis-
played malignancy the mean PASS score was 8.6 (me-
dian 9.0, range 6-11 cm, SD = 2.51) (Table III).
A positive reaction with synaptophysin was observed
in all 62 pheochromocytomas. The reaction was pres-
ent in almost all tumour cells (more than 90%)
(Fig. 1). This reaction was described as granular cy-
toplasmic staining with minimal variation of intensi-
ty: in 41 tumours (66.2%) the intensity was described
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Table III. Statistical comparison of size, PASS score and Ki-67 index in malignant (5 cases) and remaining non-malig-
nant 57 cases
MALIGNANT DIAM KI67 PASS
MEAN SD MIN MAX MEAN SD MIN MAX MEAN SD MIN MAX MEDIAN
no 4.70 2.16 1.50 11.00 1% 0.005 0% 4% 3.93 2.05 0.00 9.00 4.00
yes 8.10 2.88 5.50 13.00 3% 0.022 1% 6% 8.60 2.51 6.00 11.00 9.00
all cases 4.98 2.38 1.50 13.00 1% 0.009 0% 6% 4.36 2.43 0.00 11.00 4.00
U = 43.0, p < 0.0073 U = 62.0, p < 0.036 U=20.5, p < 0.0004
Table II. Characteristics of patients with the diagnosis
of pheochromocytoma
MALE FEMALE TOTAL
Age (y) 48.4 46.9 47.6
Site
left 11 17 28
right 17 13 30
unknown 3 1 4
Diameter (cm) 5.1 4.9 5.0
PASS 4.09 4.25 4.17
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as medium (2+) and in 21 tumours (33.8%) as
strong (3+). Each of 62 tumours with diffuse synap-
tophysin immunoreactivity also displayed a diffuse and
strong reaction with chromogranin in almost every cell
(more than 90%). The chromogranin staining was de-
scribed as granular and cytoplasmic – staining inten-
sity varied in the different areas of each tumour, as well
as in different compartments of each cell, were observed
(Fig. 2). The intensity of reaction was described as strong
(3+) in 34 cases (54.8%), both strong and medium
(3+/2+) in 24 cases (38.7%), and medium (2+) in 4
cases (6.5%). None of the 62 tumours with strong and
diffuse synaptophysin and chromogranin immunore-
activity expressed melan A or inhibin.
The two tumours that were excluded from this se-
ries had small groups of cells presenting weak (1+) ex-
pression for synaptophysin; one of them was negative
for chromogranin and in the other weak expression of
chromogranin was present in some cells. Both tumours
had strong and diffuse immunoreactivity with melan A.
They also presented weak expression of inhibin in some
cells. S-100 positive elongated cells were not present. Con-
sequently, these two tumours were re-classified as adre-
nal cortical neoplasms and were excluded from the study.
S-100 antibody staining revealed the presence of
S-100 positive elongated cells in all 62 pheochromo-
cytomas. S-100 positive cells were present at the pe-
riphery of so-called cell nests in the areas where the nests
were preserved. In the areas with solid cell growth or
in tumours which presented as cystic neoplasms filled
with blood, the distribution of S-100 positive cells was
very uneven. There was a difference between mean
count of S-100 positive cells in benign and malignant
pheochromocytomas (Table 4) but the precise count-
ing of sustentacular cells was very difficult; the S-100
positive cell count was different in different parts of the
same tumour (Fig. 3A,B). Consequently the consistency
of the results was unsatisfactory.
Fig. 1. Immunohistochemistry for synaptophysin:
granular cytoplasmic staining with homogeneous
moderate intensity is visible in the majority of cells
Fig. 2. Immunohistochemistry for chromogranin:
granular cytoplasmic staining is present in the majority
of cells. Variation in staining intensity is well visible
A B
Fig. 3. In most tumours density of S-100 positive sustentacular cells was not uniform: within an individual (single)
tumour, areas with high (A) and low (B) density were observed
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Regarding proliferation rate, 59 out of 62 tumours
had a Ki-67 index between 0 and 2% (Table V). In
three tumours the proliferation rate was higher than
2%. Two of them turned out to be malignant in the
clinical course: the first was metastatic and had a pro-
liferation activity of 6% (Fig. 4); the second recurred
and had a proliferation rate of 4%. The other pheochro-
mocytoma with a proliferation rate of 4% was a 1.5 cm
tumour found in the patient with MEN 2A syndrome
who had bilateral pheochromocytomas but no signs of
recurrence or metastasis 48 months after the operation.
Discussion
In 64 tumours diagnosed originally as pheochro-
mocytoma, immunohistochemical analysis with a pan-
el of six antibodies was performed. Both chromogranin
and synaptophysin immunoreactivity was diffusely pres-
ent in the 62 cases whose diagnosis was confirmed. The
remaining two cases were reclassified as cortical tu-
mours. The 62 pheochromocytomas did not express
melan A or inhibin. Immunoreactivity for chromogranin
and synaptophysin was described as diffuse, granular
cytoplasmic staining with variation in the intensity of
reaction in different areas of the same tumour, and for
chromogranin, also in single cells. This variation was
more pronounced for chromogranin and the overall
staining intensity was stronger for chromogranin
than for synaptophysin. There was no difference in the
intensity of staining between small and large tumours,
nor between those with benign and malignant clini-
cal outcome. Immunohistochemistry is crucial to dis-
tinguish cortical from medullary adrenal tumours, but
it is not helpful in predicting clinical behaviour of
a pheochromocytoma.
A typical pheochromocytoma has an “organoid”
structure which means that neoplastic cells are
arranged in small, usually roundish nests (referred to
as “Zellballen”) separated by thin vascular septa and
surrounded by elongated Schwann-like S-100 positive
sustentacular cells [1, 6]. In real life, however, the pres-
ence of well-defined, regular cell nests throughout the
entire tumour is rarely observed. Usually, irregularly
shaped, larger nests of neoplastic cells and trabecular
areas, as well as more solid areas, are seen at least in
some parts of the tumours. The organoid architecture
of the neoplasm is even more disorganised in tumours
with areas of haemorrhage, myxoid or hyaline stromal
change and stromal fibrosis. The reaction for S-100 pro-
tein revealed the presence of sustentacular cells in all
the 62 pheochromocytomas and absence of such cells
in the two cases reclassified as cortical tumours. Sus-
tentacular cells were present at the periphery of cell nests
in the areas where the nests were preserved, and were
more chaotically distributed in the areas with solid
growth. The mean count of the S-100 positive sus-
tentacular cells in high power fields was very uneven
and the score was dependent on the shape and size of
the cell nests. In the areas where cell nests were irregular
and bigger, S-100 positive cells were less numerous but
it was easier to count them. On the other hand, in the
areas where cell nests were roundish and small, sus-
tentacular cells were more numerous and had longer,
branching projections, making the precise counting very
difficult. We found significant differences in susten-
tacular cell number in different areas of the same tu-
mour. We also found a difference in mean count of S-
100 positive cells between benign pheochromocytomas
and the metastasizing or recurrent ones, but the final
number of sustentacular cells in any tumour depend-
ed on the areas chosen for counting. The consistency
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Table IV. Statistical comparison of mean count of S-100
positive sustentacular cells in benign and malignant
pheochromocytomas
PHEOCHROMOCYTOMA MEAN MEDIAN SD
COUNT
benign 27.5 27 17.9
malignant 22.2 19 8.43
Table V. Proliferation rate in pheochromocytomas with
benign and malignant clinical course
CLINICAL COURSE # OF CASES PROLIFERATION
RATE
benign (no metastases 56 less than 2%
no recurrent) 1 4%
malignant 2 less than 2%
(metastases) 1 6%
malignant 1 less than 2%
(recurrent) 1 4%
Fig. 4. Malignant pheochromocytoma: immunohisto-
chemistry for Ki-67
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of the results was unsatisfactory. Some authors found
an association between lower average count of S-100
positive sustentacular cells in intra-adrenal pheochro-
mocytomas or extra-adrenal tumours (paraganglioma)
and unfavourable prognosis [20, 21]. Others stated that
tumours with complete absence of sustentacular cells
in some areas had greater potential for metastasis [22].
In our opinion, the sustentacular cell count is not re-
producible in the majority of pheochromocytomas be-
cause of great variability of architectural patterns in most
tumours, as well as because the frequent extensive
haemorrhagic and cystic changes significantly disturb
the network of S-100 positive cells. That is why the
number of sustentacular cells cannot be used as a tool
in everyday pathomorphological practice and is not
helpful in predicting the clinical behaviour of pheochro-
mocytomas.
The proliferation rate was estimated as the per-
centage of tumour cells positive with the proliferation
marker Ki-67. As Ki-67 protein is present in nuclei dur-
ing the G1, S, G2 and M phases of the cell cycle (but
not in G0 phase), Ki-67 nuclear expression is charac-
teristic of cells in the cell cycle [23]. The proliferation
activity of tumour cells is a useful marker for estimating
the growth potential in many tumours. Some authors
have found a positive correlation between Ki-67 score
(proliferation activity of the tumour) and malignant be-
haviour in pheochromocytomas [9, 24, 25, 26]. How-
ever, the Ki-67 score is not a perfect tool: the score in
most pheochromocytomas is low, between 0 and 2%
[10, 22, 26]. In the present study, not only 56 un-
eventful pheochromocytomas but also three which had
a malignant clinical course had a proliferation activi-
ty between 0 and 2%. These results correspond with
those recorded in the literature [10, 22, 26]. On the
other hand, two malignant, metastatic tumours had
a proliferation rate 4% or higher. So it is probable that
tumours with high proliferation activity (over 4%) will
behave malignantly, but the proliferation activity low-
er than 4% does not exclude the malignant potential
of the tumour. One tumour with proliferation activi-
ty of 4% (found in a MEN 2A patient who had bilat-
eral pheochromocytomas) did not show evidence of ma-
lignancy during the 24-month follow-up period, but
the follow-up time is probably too short to allow any
definitive conclusion. Van der Harst et al. reported that
no benign pheochromocytomas exhibited a prolifera-
tive index greater than 2.5%, whereas 50% of malig-
nant tumours in their series did [22].
In conclusion:
1. Chromogranin and synaptophysin are useful mark-
ers to confirm the neuroendocrine nature of the tu-
mours and to make a diagnosis of pheochromocy-
toma, but the pattern of staining is not helpful in
predicting the malignant potential of the tumour.
2. Great variability of architectural patterns in any par-
ticular tumour, often extensive haemorrhagic
changes and occasional cystic changes disturb the
network of sustentacular S-100 positive cells, thus
making it impossible to achieve a precise and re-
producible sustentacular cell count in the majority
of tumours. That is why the mean sustentacular cell
count is not helpful in predicting clinical outcome
of pheochromocytoma.
3. High Ki-67 is quite specific but not sensitive
enough for diagnosing or at least predicting ma-
lignant behaviour. There is strong evidence to fol-
low up more carefully patients with pheochromo-
cytomas with a Ki-67 index of 4% or higher. We
have also obtained evidence favouring the possibil-
ity of using Ki-67 together with PASS in the iden-
tification of cases that may constitute a group of tu-
mours with malignant potential: every tumour with
a PASS score of 6 or more and Ki-67 index of 2%
or more should be followed closely.
4. Because of the above listed limitations, the presence
of metastases and/or recurrent disease still remain
the only unquestionable criterion for diagnosis of ma-
lignant pheochromocytoma.
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